Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/12/2025

Adjuvant Endocrine Therapy Duration

Maximum Duration Recommendation

  • The American Society of Clinical Oncology (ASCO) guidelines recommend that women who receive extended adjuvant endocrine therapy should receive no more than 10 years of total treatment, based on evidence from multiple trials 1, 2
  • The National Comprehensive Cancer Network (NCCN) guidelines align with this position, noting that no data support aromatase inhibitor use beyond 10 years total 3, 4

Evidence Supporting the 10-Year Limit

  • The MA.17R trial found that disease-free survival improved with extended letrozole therapy from 5 to 10 years (95% vs 91% at 5 years), but no overall survival benefit was demonstrated 3, 4
  • The MA.17R trial also found that contralateral breast cancer rates were lower with extended letrozole (0.21% vs 0.49% annually) 3, 4
  • Extended letrozole therapy was associated with increased bone-related adverse effects, including bone pain (18% vs 14%), fractures (14% vs 9%), and new-onset osteoporosis (11% vs 6%) 3, 4

Why Stop at 10 Years?

  • The risk-benefit ratio becomes unfavorable beyond 10 years, as no trials have evaluated aromatase inhibitors beyond 10 years, and the absolute benefit in disease-free survival is modest (4% difference at 5 years in MA.17R) 3, 4, 5
  • Bone health deteriorates progressively with continued therapy, increasing fracture risk, and quality of life considerations favor stopping, as menopausal symptoms and musculoskeletal complaints persist 3, 4, 5

Critical Caveats

  • Before stopping letrozole, ensure appropriate bone health management, including obtaining a final bone density assessment to determine if bone-directed therapy should continue, and continue calcium and vitamin D supplementation indefinitely 6
  • Monitor for late recurrence risk, which persists years 5-20 after diagnosis, though this doesn't justify indefinite therapy 5
  • The decision to stop at 10 years applies regardless of risk level, as even high-risk patients should not exceed 10 years total endocrine therapy, and the lack of overall survival benefit holds across all risk subgroups studied 1, 2, 3